1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Bristol-Myers Squibb Company PFD CONV 2

Bristol-Myers Squibb Company PFD CONV 2

BMYMP
Bristol-Myers Squibb Company PFD CONV 2US flagOther OTC
400.00
USD
-540.22
- -
814.59BMarket Cap

Total Valuation

Bristol-Myers Squibb Company PFD CONV 2 carries a market capitalization of 814.59B, placing it among publicly traded companies globally. Its enterprise value stands at 35.98B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap814.59B
Enterprise Value35.98B

Share Statistics

Bristol-Myers Squibb Company PFD CONV 2 currently has 2.04B shares outstanding.

Shares Outstanding2.04B
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Enterprise Valuation

On an enterprise value basis, Bristol-Myers Squibb Company PFD CONV 2 trades at an EV/EBITDA multiple of 2.09 and an EV/FCF ratio of 2.45. The EV/Sales ratio of 0.74 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 2.65 provides insight into valuation relative to core operating earnings.

EV / Sales0.74
EV / EBITDA2.09
EV / EBIT2.65
EV / FCF2.45

Financial Position

Bristol-Myers Squibb Company PFD CONV 2 maintains a current ratio of 1.42, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 230.96, indicating elevated leverage, while an interest coverage ratio of 9.50 demonstrates adequate ability to service its debt obligations.

Current Ratio1.42
Quick Ratio1.18
Debt / Equity230.96
Debt / EBITDA2.70
Interest Coverage9.50

Financial Efficiency

Bristol-Myers Squibb Company PFD CONV 2 posts a return on equity of 41.60 and a return on invested capital of 15.17.

Return on Equity (ROE)41.60
Return on Assets (ROA)8.13
Return on Invested Capital (ROIC)15.17
Return on Capital Employed (ROCE)13.03
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover5.28

Taxes

Over the trailing twelve months, Bristol-Myers Squibb Company PFD CONV 2 has paid 2.32B in income taxes, reflecting an effective tax rate of 24.22.

Income Tax2.32B
Effective Tax Rate24.22

Stock Price Statistics

Bristol-Myers Squibb Company PFD CONV 2's stock has declined approximately -46.80851% over the past 52 weeks. The 50-day moving average sits at 945.27, while the 200-day moving average is 839.91.

Beta (5Y)N/A
52-Week Price Change-46.80851%
50-Day Moving Average945.27
200-Day Moving Average839.91
Average Volume (20 Days)N/A

Income Statement

EBITDA reached 17.18B, while operating income came in at 13.59B.

Revenue48.48B
Gross Profit34.16B
Operating Income13.59B
Pretax Income9.60B
Net Income7.28B
EBITDA17.18B
EBIT13.59B
Earnings Per Share (EPS)N/A

Balance Sheet

Bristol-Myers Squibb Company PFD CONV 2 holds 10.49B in cash and equivalents against 46.43B in total debt, resulting in a net debt position of 34.89B. Total book value stands at 18.58B, with working capital of 8.05B providing operational flexibility.

Cash & Cash Equivalents10.49B
Total Debt46.43B
Net Debt34.89B
Equity (Book Value)18.58B
Book Value Per ShareN/A
Working Capital8.05B

Cash Flow

Bristol-Myers Squibb Company PFD CONV 2 produced 13.31B in operating cash flow over the past twelve months.

Operating Cash Flow13.31B
Capital ExpendituresN/A
Free Cash Flow13.31B
FCF Per ShareN/A

Margins

Bristol-Myers Squibb Company PFD CONV 2 operates with a gross margin of 70.45, reflecting its pricing power and cost economics. The operating margin of 28.03 and net profit margin of 15.01 provide insight into operational efficiency.

Gross Margin70.45
Operating Margin28.03
Pretax Margin19.79
Profit Margin15.01
EBITDA Margin35.44

Dividends & Yields

The company's payout ratio of 69.77 indicates the proportion of earnings distributed to shareholders.

Dividend Per ShareN/A
Dividend YieldN/A
Payout Ratio69.77
Shareholder YieldN/A
FCF YieldN/A

Scores

Bristol-Myers Squibb Company PFD CONV 2 posts an Altman Z-Score of 2.78, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.78